Hepaglide 0.5mg Injection is a once-weekly injectable medicine used for cardiovascular risk reduction and weight management in adults and adolescents aged 12 years and older with obesity, as well as in adults with overweight who have at least one related health condition. Supplied as 1 multi-dose disposable pen with 4 needles and 4 alcohol swabs, this is a prescription pharmaceutical product intended for subcutaneous administration under medical supervision. For B2B buyers such as hospitals, clinics, pharmacies, and healthcare distributors, Hepaglide is suitable for wholesale procurement and bulk order requirements through an OEM-relevant pharmaceutical supply chain. It is factory direct in the sense of being sourced as a finished medicinal product from the supplier, and it is export-ready subject to destination market regulations and prescription medicine controls. The minimum order quantity is 1 box, making it accessible for smaller institutional replenishment as well as routine pharmacy stocking. The product is designed for administration in the abdomen, thigh, or upper arm, with dosing taken on the same day each week to help maintain consistent therapeutic levels. When used alongside a healthy diet and regular exercise, it supports treatment goals for weight management and associated cardiovascular risk reduction. Common side effects reported include nausea, vomiting, diarrhea, stomach pain, constipation, and headache, which are generally mild to moderate and may improve as treatment continues. Before supply and dispensing, healthcare providers should review patient history for pancreatitis, diabetic retinopathy, thyroid cancer, severe gastrointestinal disorders, and any personal or family history of medullary thyroid carcinoma or MEN 2. Caution is also required when used with insulin or sulfonylureas due to the increased risk of hypoglycemia. As a regulated injectable medicine, Hepaglide is best handled through compliant pharmaceutical procurement channels with controlled storage, traceability, and professional dispensing workflows.
Key Features
| Features | Description |
|---|---|
| Product Type | 0.5mg Injection |
| Dosage Form | Multi-dose Disposable Pen |
| Pack Contents | 1 Pen, 4 Needles, 4 Alcohol Swabs |
| Administration Route | Subcutaneous Injection |
| Dosing Frequency | Once Weekly |
| Primary Use | Cardiovascular Risk Reduction and Weight Management |
| Target Patients | Adults and Adolescents 12 Years and Older with Obesity |
| Use in Overweight Adults | Adults with Overweight and at Least One Related Health Condition |
| MOQ | 1 Box |
| Store Name | KARUNESH BIOSCIENCES PRIVATE LIMITED |
| Attributes | Description |
|---|---|
| Product Title | hepaglide |
| Strength | 0.5mg |
| Dosage Form | Injection |
| Device Type | Multi-dose Disposable Pen |
| Pack Size | 1 Multi-dose Disposable Pen |
| Included Accessories | 4 Needle, 4 Alcohol Swab |
| Route of Administration | Subcutaneous |
| Dosing Frequency | Once weekly |
| Application Sites | Abdomen, thigh, or upper arm |
| Primary Indication | Cardiovascular risk reduction |
| Secondary Indication | Weight management |
| Patient Age Group | Adults and adolescents aged 12 years and older |
| Indicated Population | Adults with obesity; adults with overweight and at least one related health condition |
| Common Side Effects | Nausea, vomiting, diarrhea, stomach pain, constipation, headache |
| Caution/Contraindications | History of pancreatitis, diabetic retinopathy, thyroid cancer, severe gastrointestinal problems; personal/family history of medullary thyroid carcinoma or MEN 2 |
| Drug Interaction Caution | Use with insulin or sulfonylureas may increase risk of hypoglycemia |
| Minimum Order Quantity | 1 Box |
| Store Name | KARUNESH BIOSCIENCES PRIVATE LIMITED |
*Disclaimer: The above description has been AI-generated and has not been audited or verified for accuracy. It is recommended to verify product details independently before making any purchasing decisions.
It is used for cardiovascular risk reduction and weight management in adults and adolescents aged 12 years and older with obesity, and in adults with overweight who have at least one related health condition.
Each pack contains 1 multi-dose disposable pen, 4 needles, and 4 alcohol swabs.
It is administered as a subcutaneous injection, typically in the abdomen, thigh, or upper arm.
Hepaglide is a once-weekly injection and should be taken on the same day each week at a similar time.
The minimum order quantity is 1 box.
Patients with a history of pancreatitis, diabetic retinopathy, thyroid cancer, severe gastrointestinal problems, or a personal/family history of medullary thyroid carcinoma or MEN 2 should be reviewed carefully before use.
Yes, but caution is required because combining it with insulin or sulfonylureas may increase the risk of hypoglycemia, so dose adjustment may be needed.
Common side effects include nausea, vomiting, diarrhea, stomach pain, constipation, and headache.
Country Of Origin: India
Hepaglide 0.5mg Injection (1 Multi-dose Disposable Pen, 4 Needle, 4 Alcohol Swab) is administered as a once-weekly injection. It is generally injected under the skin in your abdomen, thigh, or upper arm. Get the injection on the same day each week, at a similar time, to maintain consistent levels in your body. Along with the treatment, maintain a healthy diet and exercise regularly for maximum benefits.
The most common side effects of Hepaglide 0.5mg Injection (1 Multi-dose Disposable Pen, 4 Needle, 4 Alcohol Swab) include nausea, vomiting, diarrhea, stomach pain, constipation, and headache. These are usually mild to moderate and tend to improve as the body adjusts to treatment. Eating smaller meals or avoiding heavy, fried foods may help ease symptoms like nausea or an upset stomach. If you experience severe or persistent side effects, consult your doctor for advice.
Before starting Hepaglide 0.5mg Injection (1 Multi-dose Disposable Pen, 4 Needle, 4 Alcohol Swab), inform your doctor about any medical conditions you have, particularly a history of pancreatitis, eye problems caused by diabetes (diabetic retinopathy), thyroid cancer, or severe gastrointestinal problems. This medicine is not recommended for individuals with a personal or family history of medullary thyroid carcinoma or those with multiple endocrine neoplasia syndrome type 2 (MEN 2).
Additionally, discuss with your doctor if you are on medications for type 2 diabetes, such as insulin or sulfonylureas; combining Hepaglide 0.5mg Injection (1 Multi-dose Disposable Pen, 4 Needle, 4 Alcohol Swab) with these medications can increase the risk of low blood sugar levels (hypoglycemia). Your doctor may need to adjust your medicine dosage to ensure safe use.
Inclusive of all taxes
You Save: 0
Ahmedabad , India
Service Provider , Manufacturer, Professional Services, Contractor, Brand Owner, Distributor, Exporter, Wholesaler, Startup
GST- 24aalck4617k1zb
